We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Machine Learning Could Reduce Hospitalizations by 30% During Pandemic

By HospiMedica International staff writers
Posted on 18 Sep 2024
Image: The machine learning model reduced hospitalizations by about 27% compared to actual and observed care (Photo courtesy of 123RF)
Image: The machine learning model reduced hospitalizations by about 27% compared to actual and observed care (Photo courtesy of 123RF)

During the COVID-19 pandemic, healthcare systems were pushed to their limits, and many facilities relied on a first-come, first-served approach or a patient's medical history to determine who received treatment. However, these methods often fail to consider the complex interactions between medications and patients, potentially overlooking those who could benefit the most from treatment. Now, new research suggests that machine learning may be a more effective way to allocate scarce treatments to vulnerable patients during public health crises.

The new study by researchers at the University of Colorado Anschutz Medical Campus (Aurora, CO, USA) highlights the potential of machine learning to more efficiently allocate medical treatments in times of shortage, such as during a pandemic. The research demonstrated that machine learning, by analyzing how different patients respond to treatment, can provide more accurate, real-time information to doctors, health systems, and public health officials than traditional allocation methods. Published in JAMA Health Forum, the study revealed that using machine learning to allocate COVID-19 treatments could reduce hospitalizations by about 27% compared to current practices.

The researchers specifically examined the use of a novel method based on Policy Learning Trees (PLTs) to optimize the distribution of COVID-19 neutralizing monoclonal antibodies (mAbs) during periods of limited availability. The PLT approach was designed to prioritize treatments for individuals most at risk of hospitalization, maximizing overall benefit by factoring in variables that influence treatment effectiveness. The machine learning model was compared to real-world allocation decisions and a standard point-based system used during the pandemic. The results showed that the PLT-based model significantly reduced expected hospitalizations compared to both observed allocations and the Monoclonal Antibody Screening Score, a commonly used tool during the pandemic. The researchers hope their findings will encourage public health agencies, policymakers, and disaster management organizations to explore machine learning as a tool for future public health crises, ensuring that treatments are allocated more effectively when resources are limited.

“Existing allocation methods primarily target patients who have a high-risk profile for hospitalizations without treatments. They could overlook patients who benefit most from treatments,” said Mengli Xiao, PhD, an assistant professor in Biostatistics and Informatics, who developed the mAb allocation system based on the machine learning. “We developed a mAb allocation point system based on treatment effect heterogeneity estimates from machine learning. Our allocation prioritizes patient characteristics associated with large causal treatment effects, seeking to optimize overall treatment benefits when resources are limited.”

Gold Member
12-Channel ECG
CM1200B
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Measuring Rod
seca 233
New
Trocar
TAN RoTaLock Trocar

Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more